This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Novo’s Catalent deal faces scrutiny over foreclosure concerns in UK, US obesity-drug market

By Jon Menon, Serafina Smith and Flavia Fortes ( March 15, 2024, 16:43 GMT | Comment) -- Novo Holdings’ $16.5 billion planned acquisition of Catalent to strengthen its leading position in the anti-obesity drugs market is already facing calls for regulators to take a closer look, because by acquiring a drug supplier, Novo could limit its rivals’ access to medicines and ultimately harm consumers. It's early days, and Novo is confident of success, but there are a range of reasons why regulators might want to take a close look.Novo Holdings’ $16.5 billion planned acquisition of Catalent to strengthen its leading position in the anti-obesity drugs market is already facing calls for regulators to take a closer look, because by acquiring a drug supplier, Novo could limit its rivals’ access to medicines and ultimately harm consumers....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login